Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nipocalimab in Adults With Moderate to Severe Sjogren's Disease
NCT06741969Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2024
- Primary completion
- Jan 2028
- Modality
- Monoclonal Antibodies
- Countries
- 28
01
Overview
A Phase 3 trial of nipocalimab in Sjogren's syndrome, sponsored by Janssen Pharmaceutical. Started Dec 2024; status: active, not recruiting.
02
Drugs
nipocalimab
03
Conditions
Sjogren's syndrome
Beyond the preview
Go deeper on NCT06741969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06741969.